Pyrovalerone

Summary

Pyrovalerone (CHEMBL201960) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 245.36 Da · C16H23NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL201960
Name	Pyrovalerone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	14373
Molecular formula	C16H23NO
Molecular weight	245.36
InChIKey	SWUVZKWCOBGPTH-UHFFFAOYSA-N

SMILES: CCCC(C(=O)C1=CC=C(C=C1)C)N2CCCC2

IUPAC name: 1-(4-methylphenyl)-2-pyrrolidin-1-ylpentan-1-one

Also known as: J8.659B, Pirovalerona, Pyrovalerone, pyrovalerone, PYROVALERONE

Parent form; salt/anhydrous children: CHEMBL2104793

Patent coverage: 195 distinct patent families (636 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Sodium-dependent dopamine transporter.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 8 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC6A3	8.1	Ki	8	nM	CHEMBL_ACT_2657852
SLC6A3	7.67	Ki	21.4	nM	CHEMBL_ACT_1682302
SLC6A2	7.55	IC50	28.3	nM	CHEMBL_ACT_1682366
SLC6A3	7.5	IC50	32	nM	CHEMBL_ACT_2657856
SLC6A3	7.28	IC50	52	nM	CHEMBL_ACT_1682362
SLC6A2	6.71	Ki	195	nM	CHEMBL_ACT_1682365
SLC6A4	5.56	IC50	2780	nM	CHEMBL_ACT_1682364
SLC6A4	5.42	Ki	3770	nM	CHEMBL_ACT_1682363

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).